Biomerica Future Growth

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biomerica has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:BMRA - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
2/29/2024	5	-6	-5	-5	N/A
11/30/2023	6	-6	-5	-5	N/A
8/31/2023	5	-6	-6	-6	N/A
5/31/2023	5	-7	-6	-5	N/A
2/28/2023	10	-7	-9	-9	N/A
11/30/2022	16	-6	-5	-5	N/A
8/31/2022	19	-5	-2	-2	N/A
5/31/2022	19	-5	-1	0	N/A
2/28/2022	15	-4	3	3	N/A
11/30/2021	11	-7	-1	-1	N/A
8/31/2021	7	-7	-4	-4	N/A
5/31/2021	7	-7	-6	-5	N/A
2/28/2021	9	-6	-8	-8	N/A
11/30/2020	6	-5	-7	-7	N/A
8/31/2020	7	-4	-6	-6	N/A
5/31/2020	7	-2	-4	-4	N/A
2/29/2020	5	-3	-2	-2	N/A
11/30/2019	5	-2	-2	-2	N/A
8/31/2019	5	-2	-2	-1	N/A
5/31/2019	5	-2	-2	-2	N/A
2/28/2019	5	-2	-2	-2	N/A
11/30/2018	5	-2	-2	-2	N/A
8/31/2018	5	-2	-2	-2	N/A
5/31/2018	6	-1	-1	-1	N/A
2/28/2018	6	-1	-1	-1	N/A
11/30/2017	6	-1	N/A	-1	N/A
8/31/2017	6	-1	N/A	-1	N/A
5/31/2017	6	-1	N/A	-1	N/A
2/28/2017	6	-2	N/A	0	N/A
11/30/2016	6	-2	N/A	0	N/A
8/31/2016	5	-1	N/A	0	N/A
5/31/2016	5	-1	N/A	0	N/A
2/29/2016	5	0	N/A	0	N/A
11/30/2015	5	0	N/A	-1	N/A
8/31/2015	5	0	N/A	-1	N/A
5/31/2015	5	0	N/A	0	N/A
2/28/2015	5	0	N/A	0	N/A
11/30/2014	5	0	N/A	0	N/A
8/31/2014	5	0	N/A	0	N/A
5/31/2014	5	0	N/A	-1	N/A
2/28/2014	5	0	N/A	-1	N/A
11/30/2013	5	0	N/A	0	N/A
8/31/2013	6	0	N/A	1	N/A
5/31/2013	6	1	N/A	1	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if BMRA's forecast earnings growth is above the savings rate (2.4%).

Earnings vs Market: Insufficient data to determine if BMRA's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if BMRA's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if BMRA's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if BMRA's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if BMRA's Return on Equity is forecast to be high in 3 years time

Biomerica Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Forecast to breakeven in 2023

Price target increased to US$13.00

Biomerica, Inc. Provides Earnings Guidance for the Second Quarter Ended November 30, 2021

Price target increased to US$13.00

Biomerica, Inc.'s (NASDAQ:BMRA) Profit Outlook

Analysts lower revenue estimates to US$8.51m

Recent updates

Third quarter 2024 earnings released: US$0.11 loss per share (vs US$0.12 loss in 3Q 2023)

Biomerica, Inc. Announces the Appointment of Gary Huff to Its Strategic Advisory Board

Biomerica, Inc. Appoints Jack Kenny as Chairman of the Board of Directors

Second quarter 2024 earnings released: US$0.09 loss per share (vs US$0.12 loss in 2Q 2023)

Is Biomerica (NASDAQ:BMRA) In A Good Position To Deliver On Growth Plans?

Biomerica, Inc. Receives US FDA 510(k) Clearance for their Hp Detect Stool Antigen ELISA Test Product Designed to Detect Presence of H. Pylori Bacteria

First quarter 2024 earnings released: US$0.067 loss per share (vs US$0.16 loss in 1Q 2023)

Biomerica, Inc., Annual General Meeting, Dec 07, 2023

Here's Why We're Watching Biomerica's (NASDAQ:BMRA) Cash Burn Situation

Jack Kenny Joins Biomerica’S Board of Directors

Full year 2023 earnings released: US$0.50 loss per share (vs US$0.36 loss in FY 2022)

Biomerica Inc. Receives Notice of Patent Allowance in China for A Potential Innovative Technology That Includes an Artificial Intelligence Claim for Predicting Foods That Contain Ingredients That Cause Adverse Reactions in Patients

Biomerica Inc. Announces A Significant Advance in the Management of Irritable Bowel Syndrome

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.008 loss in 3Q 2022)

We're Keeping An Eye On Biomerica's (NASDAQ:BMRA) Cash Burn Rate

Second quarter 2023 earnings released: US$0.12 loss per share (vs US$0.089 loss in 2Q 2022)

Biomerica Appoints Brian E. Lacy, to the Company’s Scientific Advisory Board

Steve Sloan to Step Down as Chief Financial Officer of Biomerica, Inc

Biomerica, Inc. Announces Board Changes

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.12 loss in 1Q 2022)

Amazon starts selling Biomerica's Aware Breast Self Exam device, EZ Detect test

Biomerica, Inc., Annual General Meeting, Dec 07, 2022

Biomerica: One To Watch Closely For The Future, But From The Sidelines For Now

Biomerica, Inc. Appoints Robert Carlson as Chief Commercial Officer

Full year 2022 earnings released: US$0.36 loss per share (vs US$0.62 loss in FY 2021)

Biomerica reports FY results

Biomerica stock jumps after Walmart to begin selling co's Aware Breast Self Exam device

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Forecast to breakeven in 2023

Price target increased to US$13.00

Biomerica, Inc Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods® IBS Treatment for Patients with Irritable Bowel Syndrome

Biomerica, Inc. Provides Earnings Guidance for the Second Quarter Ended November 30, 2021

Most Shareholders Will Probably Find That The CEO Compensation For Biomerica, Inc. (NASDAQ:BMRA) Is Reasonable

Biomerica (NASDAQ:BMRA) Is In A Good Position To Deliver On Growth Plans

First quarter 2022 earnings released: US$0.12 loss per share (vs US$0.14 loss in 1Q 2021)

Is Biomerica Stock A Buy Or Sell After Q4 Earnings? Catalysts To Watch Into 2022

Biomerica, Inc. Expects Completion of Patient Enrollment for Its Infoods Diagnostic-Guided Therapy Irritable Bowel Syndrome Clinical Trial This Week

Price target increased to US$13.00

Full year 2021 earnings released: US$0.54 loss per share (vs US$0.23 loss in FY 2020)

Biomerica Announces Notice of Allowance for Patent on Product Used to Diagnose and Treat Depression

Biomerica, Inc. Receives Notice of Allowance from Mexican Patent Office for Irritable Bowel Syndrome Food Sensitivity Testing & Treatment

Biomerica (BMRA) Investor Presentation - Slideshow

Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.088 loss in 3Q 2020)

Biomerica, Inc.'s (NASDAQ:BMRA) Profit Outlook

Should You Review Recent Insider Transactions At Biomerica, Inc. (NASDAQ:BMRA)?

New 90-day high: US$8.00

Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth

New 90-day high: US$7.50

Second quarter 2021 earnings released: US$0.13 loss per share

Earnings beat expectations, revenue disappoints

The Biomerica (NASDAQ:BMRA) Share Price Has Soared 405%, Delighting Many Shareholders

Biomerica, Inc. Receives CE Mark for its New Covid-19 Rapid Antigen Test for Detection of Covid-19 Infection

Analysts lower revenue estimates to US$8.51m

Biomerica soars as its COVID-19 antigen test wins European nod

When Will Biomerica, Inc. (NASDAQ:BMRA) Become Profitable?

New 90-day low: US$5.38

Biomerica, Inc. Announces Corporate Secretary Changes

Biomerica's InFoods® Irritable Bowel Syndrome Diagnostic-Guided Therapy Clinical Trial Nears Completion of Enrollment

Biomerica clinical trial for IBS nears enrollment completion

How Much Does Biomerica's (NASDAQ:BMRA) CEO Make?

Analysts update estimates

First-quarter earnings released: Revenue and earnings miss expectations

First quarter earnings released

New 90-day low: US$5.84

Analysts update estimates

Analysts increase EPS estimates to -US$0.087

Full year earnings released - US$0.23 loss per share

Biomerica, Inc. to Report Fiscal Year 2020 Results on Aug 31, 2020